ASGCT 2026 oral session meeting summary: AAV cell line development and engineering
Molecular Therapy · 2026-08 · 34 (8) · 4344-4346
DOI: 10.1016/j.ymthe.2026.07.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-08. Verfasst von Frank Agbogbo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Forge Biologics, Grove City, OH, USA. Electronic address: fagbogbo@forgebiologics.com. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Forge Biologics, Grove City, OH, USA. Electronic address: fagbogbo@forgebiologics.com.
- Cytiva, Cologne, Germany.
- NewBiologix SA, Epalinges, Switzerland.
- Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA.
- iBET - Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
- PackGene Biotech, Houston, TX, USA.
Zitieren
APA
Agbogbo, F., Hussong, M., Guzman, E., Doleh, E., Blenner, M., Escandell, J., & Li, R. (2026). ASGCT 2026 oral session meeting summary: AAV cell line development and engineering. Molecular Therapy, 34(8), 4344-4346. https://doi.org/10.1016/j.ymthe.2026.07.027
Vancouver
Agbogbo F, Hussong M, Guzman E, Doleh E, Blenner M, Escandell J, et al. ASGCT 2026 oral session meeting summary: AAV cell line development and engineering. Molecular Therapy. 2026;34(8):4344-4346. doi:10.1016/j.ymthe.2026.07.027
BibTeX
@article{Agbogbo2026,
author = {Agbogbo, Frank and Hussong, Michelle and Guzman, Efrain and Doleh, Emily and Blenner, Mark and Escandell, Jose and Li, Ran},
title = {ASGCT 2026 oral session meeting summary: AAV cell line development and engineering},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {8},
pages = {4344--4346},
doi = {10.1016/j.ymthe.2026.07.027}
}
EUVIMED